miRagen Therapeutics' Director of Biology to Give Plenary Lecture at Center for Heart Failure Research Symposium in Oslo, Norway
9/30/2010 9:07:27 AM
BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that its Director of Biology, Eva van Rooij, Ph.D., will give a plenary lecture today at the 8th Annual Center for Heart Failure Research Symposium in Oslo, Norway. Dr. van Rooij’s talk, titled “Oligonucleotide-based modulation of microRNAs to control cardiovascular disease,” will review the basis for the development of a modified short nucleic acid sequence targeting microRNA-208 (antimiR-208) as a strategy for intervention in heart disease and introduce compelling new data supporting its potential as a therapeutic agent. Data to be highlighted include antimiR-208 in hypertensive rodent models of heart failure and preliminary dose ranging and toxicology analysis in non-human primates.
comments powered by